Dejan Juric

Oncology

55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 134 publications

Perceptions of Prognosis and Hope Among Patients With Advanced Cancer at the Time of Enrollment in an Early-Phase Clinical Trial.

Perceptions of Prognosis and Hope Among Patients With Advanced Cancer at the Time of Enrollment in an Early-Phase Clinical Trial.

Journal: JCO oncology practice

Published: March 20, 2026

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Journal: ESMO open

Published: January 16, 2026

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Journal: Cancer discovery

Published: October 07, 2025

Associations of symptom burden with patient-reported outcomes and clinical outcomes among early phase cancer clinical trial participants.

Associations of symptom burden with patient-reported outcomes and clinical outcomes among early phase cancer clinical trial participants.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: September 29, 2025

Use of supportive care services and advance care planning among early phase oncology clinical trial participants.

Use of supportive care services and advance care planning among early phase oncology clinical trial participants.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: July 31, 2025

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 27, 2025

Buenos Aires Breast Cancer Symposium 2024: bridging basic and clinical research in breast cancer.

Buenos Aires Breast Cancer Symposium 2024: bridging basic and clinical research in breast cancer.

Journal: Medicina

Published: June 27, 2025

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: June 02, 2025

A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.

A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.

Journal: Cancer research communications

Published: May 14, 2025

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

Journal: The Lancet. Oncology

Published: May 07, 2025

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Journal: Cancer research

Published: April 28, 2025

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 20, 2025

Showing 1-12 of 134

Last Updated: 09/26/2026